Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | TACR2 | P21452 | 14/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638920 | 0.93 | TACR3 (0.57) | TACR3TACR2APAF1UBE2NTACR1 | |
| SCHEMBL3862800 | 0.90 | TACR3 (0.52) | TACR3TACR2APAF1UBE2NTACR1 | |
| SCHEMBL3862557 | 0.90 | TACR2 (0.44) | TACR3TACR2TACR1 | |
| SCHEMBL8802198 | 0.89 | TACR3 (0.53) | TACR3TACR2APAF1UBE2NTACR1 | |
| SCHEMBL3862765 | 0.89 | TACR3 (0.50) | TACR3TACR2TACR1 | |
| SCHEMBL3862793 | 0.88 | TACR3 (0.48) | TACR3TACR2APAF1UBE2NTACR1 | |
| SCHEMBL3856590 | 0.84 | TACR3 (0.48) | TACR3TACR2APAF1UBE2NTACR1 | |
| SCHEMBL8801936 | 0.83 | TACR2 (0.51) | TACR3TACR2TACR1CCR5 | |
| SCHEMBL3637661 | 0.83 | TACR2 (0.44) | TACR2TACR1CCR5 | |
| SCHEMBL8802349 | 0.82 | HTR1A (0.48) | TACR3TACR2POLBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | DRD3, KCND3, GRIN3A | TACR3 107/4885TACR2 30/4885APAF1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.